SCHEMBL26611

SCHEMBL26611

[CH2]COCCN(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264783 0.95 CA12 (0.47)
SCHEMBL4273359 0.95 CA12 (0.47)
SCHEMBL4274493 0.83
SCHEMBL5347142 0.81 ALDH1A1 (0.48)
SCHEMBL15091 0.81 CA12 (0.52)
SCHEMBL2106534 0.80
SCHEMBL9655042 0.78
Hydrochloric Acid SCHEMBL473385 0.78 CA12 (0.50)
SCHEMBL3973874 0.78 CA12 (0.56)
Water SCHEMBL2217898 0.78 CA12 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6293 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4396349-A1 COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION Molecular Axiom, LLC (US) 2024-07-10 EP claimed
EP-4395901-A1 COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION Molecular Axiom, LLC (US) 2024-07-10 EP claimed
CN-111902148-B Compositions and methods for treating muscular atrophy and tonic muscular dystrophy 艾维迪提生物科学公司 2024-07-05 CN claimed
CN-118267396-A Nucleic acid-polypeptide compositions and uses thereof 艾维迪提生物科学公司 2024-07-02 CN claimed
WO-2024134505-A1 NUCLEIC ACID LIGATION METHOD NOVARTIS AG (CH) 2024-06-27 WO claimed
WO-2024137663-A2 TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-27 WO claimed
WO-2024134502-A1 ENGINEERED DOUBLE-STRAND RNA LIGASES AND USES THEREOF NOVARTIS AG (CH) 2024-06-27 WO claimed
CN-118251494-A Compositions and methods for modulating KRAS expression 美国微哲默理有限责任公司 2024-06-25 CN claimed
WO-2024129886-A2 TREATMENT OF MST1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-20 WO claimed
WO-2024121576-A1 AFFINITY PROBES Qbiotix Limited (GB) 2024-06-13 WO claimed
EP-1038894-A2 New catalyst compositions for the production of polyurethanes AIR PRODUCTS AND CHEMICALS, INC. (US) 2000-09-27 EP claimed
JP-2778632-B2 1998-07-23 JP claimed
US-5731128-A ELASTICITY, HARDNESS, ELONGATION; WATER DEVELOPABILITY NIPPON PAINT CO., LTD. (JP) 1998-03-24 US claimed
EP-0688786-B1 New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardio-vascular system, processes for their preparation and pharmaceutical compositions containing same SIGMA TAU IND FARMACEUTI (IT) 1997-08-06 EP claimed
EP-0688786-A1 New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardio-vascular system, processes for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1995-12-27 EP claimed
EP-0572557-A4 TREATMENT OF OVARIAN CANCER 1993-12-29 EP claimed
EP-0572557-A1 TREATMENT OF OVARIAN CANCER SMITHKLINE BEECHAM CORPORATION (US) 1993-12-08 EP claimed
EP-0282069-B1 BICYCLIC AMINOCATALYSTS RWE-DEA Aktiengesellschaft für Mineraloel und Chemie (DE) 1993-06-09 EP claimed
WO-1992014469-A1 TREATMENT OF OVARIAN CANCER SMITHKLINE BEECHAM CORPORATION (US) 1992-09-03 WO claimed
EP-0282069-A2 Bicyclic aminocatalysts RWE-DEA Aktiengesellschaft für Mineraloel und Chemie (DE) 1988-09-14 EP claimed